SCHEMBL1400959

SCHEMBL1400959

O=C1CCN(Cc2ccccc2)CC1c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 6/20 0.61
SIGMAR1 Q99720 2/20 0.48
GRIN1 Q05586 1/20 0.48
GRIN2B Q13224 1/20 0.48
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CHRM2 P08172 1/20 0.45
CHRM3 P20309 1/20 0.45
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
BACE1 P56817 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6440459 0.91 TACR1 (0.64) TACR1SIGMAR1CYP1A2CYP3A4CYP2D6
SCHEMBL1916289 0.91 TACR1 (0.51) TACR1SIGMAR1CYP1A2CYP3A4CYP2D6
SCHEMBL6439506 0.90 TACR1 (0.54) TACR1SIGMAR1GRIN1GRIN2BALDH1A1
SCHEMBL6440867 0.90 TACR1 (0.65) TACR1SIGMAR1GRIN1GRIN2BBCHE
Hydrochloric Acid SCHEMBL3290339 0.90 TACR1 (0.52) TACR1SIGMAR1CYP1A2CYP3A4CYP2D6
SCHEMBL3902021 0.88 TACR1 (0.54) TACR1SIGMAR1ALDH1A1
SCHEMBL3997201 0.85 TACR1 (0.52) TACR1SIGMAR1
SCHEMBL3900026 0.84 ESR1 (0.50) TACR1SIGMAR1CHRM2CHRM3HPGD
SCHEMBL1617423 0.82 TACR1 (0.56) TACR1SIGMAR1GRIN1GRIN2BCYP1A2
SCHEMBL1617419 0.82 TACR1 (0.50) TACR1SIGMAR1GRIN1GRIN2BCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1581518-B1 SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2011-03-02 EP disclosed
US-7795261-B2 Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists JANSSEN PHARMACEUTICA NV (BE) 2010-09-14 US disclosed
CN-100586945-C Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists JANSSEN PHARMACEUTICA NV 2010-02-03 CN disclosed
US-7622487-B2 Piperidine derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20060167052-A1 Piperidine derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-27 US disclosed
US-20060040950-A1 Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2006-02-23 US disclosed
CN-1726207-A Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists JANSSEN PHARMACEUTICA NV (BE) 2006-01-25 CN disclosed
CN-1229373-C Piperidinee derivatives as neurokinin/antagonists HOFFMANN LA ROCHE (CH) 2005-11-30 CN disclosed
EP-1581518-A2 SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2005-10-05 EP disclosed
CN-1671662-A Piperidine derivatives, process for their preparation and their use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2005-09-21 CN disclosed
EP-1553084-A1 PIPERIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-07-13 EP disclosed
EP-1360184-B1 PIPERIDINE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2005-03-30 EP disclosed
WO-2004056799-A2 SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2004-07-08 WO disclosed
CN-1491222-A piperidine derivatives as neurokinin 1 antagonists - 2004-04-21 CN disclosed
EP-1360184-A1 PIPERIDINEE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-11-12 EP disclosed
US-6642226-B2 Such as cis-(3,5-bis-trifluoromethyl-phenyl)-(4-(4-methyl-piperazin-1-yl),-3-phenyl -piperidin-1-yl)-methanone; for treatment of diseases related to neurokinin receptors HOFFMAN-LA ROCHE INC. 2003-11-04 US disclosed
US-20020151547-A1 Substituted phenyl-piperidine methanone compounds F.HOFFMANN-LA ROCHE AG (CH) 2002-10-17 US disclosed
WO-2002062784-A1 PIPERIDINEE DERIVATIVES AS NEUROKININ 1 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167052-A1 Piperidine derivative, process for producing the same, and use OPRL1, OXTR, OPRM1 TACR1 6/4885SIGMAR1 426/4885GRIN1 341/4885
US-20020151547-A1 Substituted phenyl-piperidine methanone compounds TACR1, OPRK1, TACR2 TACR1 1/4885SIGMAR1 27/4885GRIN1 406/4885
US-20060040950-A1 Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists NPSR1, TACR1, VIP TACR1 2/4885SIGMAR1 452/4885GRIN1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.